Combination Weight Loss (CagriSema) Extensive Research The Phase 3 REDEFINE 1 trial demonstrated that CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) produced mean weight loss of 20.4% at 68 weeks in 3,417 adults with obesity or overweight without diabetes, compared to 14.9% with semaglutide alone, 11.5% with cagrilintide alone, and 3.0% with placebo
Think of it like a tiny protein
Reduces wrinkles, imparting a rejuvenated and radiant visage
While generally well-tolerated, some individuals may experience digestive upset, headaches, or fatigue, with rarer reactions requiring professional medical guidance
30mg vial30mg/vial Research watchlist Get updates when availability, evidence, or category guidance changes for Selank